The effect of Lactobacillus reuteri DSM17648 supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study

Results: After a 28-day supplementation phase with Pylopass™ there was a trend for reduction of H. pylori load in 62.5% of the subjects and for the overall GSRS scores in 66.7% of subjects.

Conclusion: The results demonstrated that L. reuteri DSM17648 has the potential to suppress H. pylori infection, and may lead to an improvement of H. pylori-associated gastro intestinal symptoms.

Shopping Cart
Scroll to Top

New Name. New Website.

We have changed our name from Nouveau Health to Nouveau Healthcare and we've moved from nouveauhealth.co.uk to nhinnovations.com.

We hope you enjoy using your new platform.